Discovery and Structure−Activity Relationship of 3-Methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): A Highly Selective 5-Hydroxytryptamine2A Receptor Inverse Agonist for the Treatment of Arterial Thrombosis-Reference-Cited by-同舟云学术

Discovery and Structure−Activity Relationship of 3-Methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): A Highly Selective 5-Hydroxytryptamine2A Receptor Inverse Agonist for the Treatment of Arterial Thrombosis

Published:2010-05-10 Issue:11 Volume:53 Page:4412-4421
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Xiong Yifeng¹,Teegarden Bradley R.¹,Choi Jin-Sun Karoline¹,Strah-Pleynet Sonja¹,Decaire Marc¹,Jayakumar Honnappa¹,Dosa Peter I.¹,Casper Martin D.¹,Pham Lan¹,Feichtinger Konrad¹,Ullman Brett¹,Adams John¹,Yuskin Diane¹,Frazer John¹,Morgan Michael¹,Sadeque Abu¹,Chen Weichao¹,Webb Robert R.¹,Connolly Daniel T.¹,Semple Graeme¹,Al-Shamma Hussien¹

Affiliation:

1. Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San Diego, California 92121

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm100044a

Reference23 articles.

1. Thrombin Receptor (Protease Activated Receptor-1) Antagonists as Potent Antithrombotic Agents with Strong Antiplatelet Effects

2. Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity

3. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study